BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23813855)

  • 1. Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents.
    Tintori C; Laurenzana I; La Rocca F; Falchi F; Carraro F; Ruiz A; Esté JA; Kissova M; Crespan E; Maga G; Biava M; Brullo C; Schenone S; Botta M
    ChemMedChem; 2013 Aug; 8(8):1353-60. PubMed ID: 23813855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors.
    Koda Y; Kikuzato K; Mikuni J; Tanaka A; Yuki H; Honma T; Tomabechi Y; Kukimoto-Niino M; Shirouzu M; Shirai F; Koyama H
    Bioorg Med Chem Lett; 2017 Nov; 27(22):4994-4998. PubMed ID: 29037944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel virtual lead identification in the discovery of hematopoietic cell kinase (HCK) inhibitors: application of 3D QSAR and molecular dynamics simulation.
    Bavi R; Kumar R; Rampogu S; Kim Y; Kwon YJ; Park SJ; Lee KW
    J Recept Signal Transduct Res; 2017 Jun; 37(3):224-238. PubMed ID: 27485399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtle Dynamic Changes Accompany Hck Activation by HIV-1 Nef and are Reversed by an Antiretroviral Kinase Inhibitor.
    Wales TE; Hochrein JM; Morgan CR; Emert-Sedlak LA; Smithgall TE; Engen JR
    Biochemistry; 2015 Oct; 54(41):6382-91. PubMed ID: 26440750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hck inhibitors as potential therapeutic agents in cancer and HIV infection.
    Musumeci F; Schenone S; Brullo C; Desogus A; Botta L; Tintori C
    Curr Med Chem; 2015; 22(13):1540-64. PubMed ID: 25666803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine-phosphorylated STAT5 accumulates on podosomes in Hck-transformed fibroblasts and chronic myeloid leukemia cells.
    Poincloux R; Cougoule C; Daubon T; Maridonneau-Parini I; Le Cabec V
    J Cell Physiol; 2007 Oct; 213(1):212-20. PubMed ID: 17503465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity cliff for 7-substituted pyrrolo-pyrimidine inhibitors of HCK explained in terms of predicted basicity of the amine nitrogen.
    Yuki H; Kikuzato K; Koda Y; Mikuni J; Tomabechi Y; Kukimoto-Niino M; Tanaka A; Shirai F; Shirouzu M; Koyama H; Honma T
    Bioorg Med Chem; 2017 Aug; 25(16):4259-4264. PubMed ID: 28662963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD45RO suppresses human immunodeficiency virus type 1 replication in microglia: role of Hck tyrosine kinase and implications for AIDS dementia.
    Kim MO; Suh HS; Si Q; Terman BI; Lee SC
    J Virol; 2006 Jan; 80(1):62-72. PubMed ID: 16352531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells.
    Manetti F; Pucci A; Magnani M; Locatelli GA; Brullo C; Naldini A; Schenone S; Maga G; Carraro F; Botta M
    ChemMedChem; 2007 Mar; 2(3):343-53. PubMed ID: 17295370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
    Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
    Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains.
    Stanglmaier M; Warmuth M; Kleinlein I; Reis S; Hallek M
    Leukemia; 2003 Feb; 17(2):283-9. PubMed ID: 12592324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
    Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
    Jin F; Gao D; Wu Q; Liu F; Chen Y; Tan C; Jiang Y
    Bioorg Med Chem; 2013 Sep; 21(18):5694-706. PubMed ID: 23932071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation.
    Pecquet C; Nyga R; Penard-Lacronique V; Smithgall TE; Murakami H; Régnier A; Lassoued K; Gouilleux F
    Oncogene; 2007 Mar; 26(11):1577-85. PubMed ID: 16953222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic cell kinase (Hck) isoforms and phagocyte duties - from signaling and actin reorganization to migration and phagocytosis.
    Guiet R; Poincloux R; Castandet J; Marois L; Labrousse A; Le Cabec V; Maridonneau-Parini I
    Eur J Cell Biol; 2008 Sep; 87(8-9):527-42. PubMed ID: 18538446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors.
    Zhu W; Sun C; Xu S; Wu C; Wu J; Xu M; Zhao H; Chen L; Zeng W; Zheng P
    Bioorg Med Chem; 2014 Dec; 22(24):6746-54. PubMed ID: 25468038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
    Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
    Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.